Key Takeaways
- MEM-ANT3310 and radiprodil, from Antabio and GRIN Therapeutics respectively, are the latest investigational products to make it onto the European Medicines priority medicines (PRIME) scheme.
- MEM-ANT3310 addresses antimicrobial resistance in severe hospital infections, while radiprodil targets GRIN-related neurodevelopmental disorder, a condition for which there are currently no approved therapies.
- PRIME enables the EMA to offer companies early and enhanced support that can help them optimize their development plans.
- The Pink Sheet’s PRIME tracker provides the status of all 148 products that have been accepted onto the scheme to date.
MEM-ANT3310, which Antabio is developing to address antimicrobial resistance (AMR) in severe hospital infections, is among the latest products to secure a place on PRIME, the European Medicines Agency’s priority...
The next-generation, broad-spectrum antibacterial is for treating infections due to aerobic Gram-negative organisms in adults with limited treatment options. It has been designed to make a significant impact on the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?